title: Human induced pluripotent stem cell and nanotechnology-based therapeutics.
abstract: Human induced pluripotent stem cells (hiPSCs) can be genetically reprogrammed to an embryonic stem cell-like state and can provide promising medical applications, such as diagnosis, prognosis, drug screening for therapeutical development, and monitoring disease progression. Despite myriad advances, traditional viral-based reprogramming for generating hiPSCs has safety risks that hinder further practical applications of hiPSCs. In the past decade, nonviral-based reprogramming has been used as an alternative to produce hiPSCs and enhance their differentiation. In addition, the efficiency of nonviral-based reprogramming is generally poor, compared to that of viral-based reprogramming. Recent studies in nanoscale-structured particles have made progress in addressing many applications of hiPSCs for clinical practice. The combination of hiPSCs and nanotechnology will actually act as the therapeutic platform for personalized medicine and can be the remedies against various diseases in the future. In this article, we review recent advances in cellular reprogramming and hiPSC-related research, such as cell source, delivery system, and direct reprogramming, as well as some of its potential clinical applications, including mitochondrial and retinal disease. We also briefly summarize the current incorporation of nanotechnology in patient-specific hiPSCs for future treatments.
authors.affiliation: Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, ROC.
authors.forename: Wei-Hsiu
authors.initials: WH
authors.lastname: Liu
authors.forename: Yuh-Lih
authors.initials: YL
authors.lastname: Chang
authors.forename: Wen-Liang
authors.initials: WL
authors.lastname: Lo
authors.forename: Hsin-Yang
authors.initials: HY
authors.lastname: Li
authors.forename: Chia-Wei
authors.initials: CW
authors.lastname: Hsiao
authors.forename: Chi-Hsien
authors.initials: CH
authors.lastname: Peng
authors.forename: Shih-Hwa
authors.initials: SH
authors.lastname: Chiou
authors.forename: Hsin-I
authors.initials: HI
authors.lastname: Ma
authors.forename: Shih-Jen
authors.initials: SJ
authors.lastname: Chen
mesh_terms: D000818:Animals; D065150:Cellular Reprogramming; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000637:transplantation*; D028361:Mitochondrial Diseases / Q000628:therapy; D053758:Nanoparticles / Q000008:administration & dosage* / Q000627:therapeutic use; D057285:Precision Medicine; D012164:Retinal Diseases / Q000628:therapy; D000068936:Theranostic Nanomedicine / Q000379:methods*